NGI 226
Alternative Names: NGI-226Latest Information Update: 28 Sep 2024
At a glance
- Originator Novartis
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Tendon injuries
Most Recent Events
- 28 Sep 2024 No recent reports of development identified for phase-I development in Tendon injuries in Switzerland
- 07 Feb 2024 Novartis announces intention to submit regulatory applications for Tendon injuries in or after 2027 (Novartis pipeline, February 2024)
- 14 Jun 2023 Phase-II clinical trials in Tendon injuries (In the elderly, In adults) in United Kingdom, France, Germany (Parenteral), after June 2023 (NCT05592990)